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Abstract
Background: Comorbidity measures, such as the Charlson Comorbidity Index (CCI) and Elixhauser Method (EM), are
frequently used for risk-adjustment by healthcare researchers. This study sought to create CCI and EM lists of Read
codes, which are standard terminology used in some large primary care databases. It also aimed to describe and
compare the predictive properties of the CCI and EM amongst patients with hip fracture (and matched controls) in
a large primary care administrative dataset.
Methods: Two researchers independently screened 111,929 individual Read codes to populate the 17 CCI and
31 EM comorbidity categories. Patients with hip fractures were identified (together with age- and sex-matched
controls) from UK primary care practices participating in the Clinical Practice Research Datalink (CPRD). The
predictive properties of both comorbidity measures were explored in hip fracture and control populations using
logistic regression models fitted with 30- and 365-day mortality as the dependent variables together with tests of
equality for Receiver Operating Characteristic (ROC) curves.
Results: There were 5832 CCI and 7156 EM comorbidity codes. The EM improved the ability of a logistic regression
model (using age and sex as covariables) to predict 30-day mortality (AUROC 0.744 versus 0.686). The EM alone also
outperformed the CCI (0.696 versus 0.601). Capturing comorbidities over a prolonged period only modestly
improved the predictive value of either index: EM 1-year look-back 0.645 versus 5-year 0.676 versus complete record
0.695 and CCI 0.574 versus 0.591 versus 0.605.
Conclusions: The comorbidity code lists may be used by future researchers to calculate CCI and EM using records
from Read coded databases. The EM is preferable to the CCI but only marginal gains should be expected from
incorporating comorbidities over a period longer than 1 year.
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Background
The comparison of patient outcomes between healthcare
providers requires effective risk adjustment for patient
characteristics. In particular, comorbidities are important
predictors of outcome1 2. Comorbidity summary mea-
sures have been developed to help classify patients
according to their overall disease burden [1–4].
The most commonly used summary measure is the
Charlson Comorbidity Index (CCI) [4]. Charlson et al.
identified 17 diseases that optimally predict one-year mor-
tality when assigned a weight between 1 (e.g. peripheral
vascular disease) and 6 (e.g. metastatic cancer) [1]. Al-
though the CCI is commonly used [4] and has been widely
validated [5], it was developed in the 1980s and has been
criticized as outdated [6]. A number of meta-analyses have
found that an alternative summary measure proposed by
Elixhauser et al. [2] has superior predictive properties3 4.
In particular, the Elixhauser Method (EM) predicts mor-
tality more effectively than CCI amongst patients with
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fractures of the cervical spine [7] and proximal humerus
[8]. However, although older adults with hip fractures have
a high comorbid disease burden, it is unclear which sum-
mary measure optimally predicts mortality in this popula-
tion. The EM is similar to the CCI (nine categories
overlap the two measures: diabetes [uncomplicated and
complicated], congestive heart failure, HIV, metastatic
cancer, renal disease, chronic pulmonary disease, rheum-
atic disease, and peripheral vascular disease) but includes
almost twice as many diagnostic categories [9].
A number of algorithms have been developed to deter-
mine CCI and EM from administrative databases based
on ICD-9 [10–12] and ICD-10 [9] diagnostic codes. Al-
though Khan et al [13] have developed an algorithm for
calculating CCI in Read-coded databases; there is no
equivalent translation for EM. This is important because
Read codes are used by General Practitioners throughout
the United Kingdom National Health Service (NHS) [14]
and are the basis on which a number of national primary
care datasets have developed. These include the Clinical
Practice Research Datalink (CPRD) GOLD [15] and The
Health Improvement Network (THIN) [16] databases.
The aims of this study were to: (1) develop coding
algorithms for calculating CCI and EM in Read-coded
databases, (2) describe the comorbidity characteristics of
a hip fracture cohort with matched controls, and (3)
compare the predictive properties of the CCI (both ori-
ginal and modified versions) and the EM.
Methods
Defining co-morbidity algorithms
The multi-step process for selecting comorbidity diag-
nostic codes is shown by Figs. 1 and 2. First, the 31 co-
morbidities defined by Elixhauser et al. [2] and 17 by
Charlson et al. [1] were extracted from their original
publications. The Charlson paper was supplemented
with work by Deyo et al. [11] who previously translated
the Charlson co-morbidities into ICD-9-CM codes. Each
comorbidity category was presented together with its
ICD-9-CM codes and a text interpretation of each code
(exploded to show the full hierarchy of sub-codes) from
the 6th edition of the International Classification of Dis-
eases, 9th Revision, Clinical Modification (ICD-9-CM)
[17]. This step was necessary because many Read terms
are unstructured but the ICD-9-CM hierarchy acted as
an aide memoire for diagnoses that might otherwise be
missed. For example, clinicians trying to populate the
Charlson category “Any malignancy, including leukaemia
and lymphoma” might search for “lymphoma” but could
inadvertently omit “mycosis fungoides” (represented by
7 separate Read codes) or “Letterer-Siwe disease” (5
Read codes). However, the researchers would encounter
Fig. 1 Flow chart showing the exclusion of Charlson co-morbidity Read codes
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all three codes while working through the “Malignant
neoplasm of lymphatic and hematopoietic tissue” chap-
ter of ICD-9-CM. Similarly, even a specialist might
search for “myeloid sarcoma” but not think to search for
additional Read codes under “chloroma”. They would
however find “chloroma” listed under “myeloid sarcoma”
in the ICD-9-CM hierarchy.
Two clinicians independently used the exploded ICD-9-
CM text codes to search all 111,929 Read terms within the
CPRD Medical Dictionary [18]. The general search princi-
ples and assumptions agreed by the two code screeners are
available in Additional file 3 The result of this process was
that each screener developed a list of Read terms that cor-
responded to the ICD-9-CM codes recommended by Elix-
hauser [2] and Charlson/Deyo [1, 11].
In addition, the online ClinicalCodes Repository [19]
was manually searched for all pre-existing Read code
lists that pertained to each comorbidity category. Lists
from 12 studies [20–30] were included from the Clini-
calCodes Repository in addition to the CCI list previ-
ously developed by Khan et al [13]. The outcome of this
process was that between two and six independent Read
code lists were generated for each comorbidity category.
The two clinicians then resolved discrepancies through
discussion and with advice from sub-specialists where
appropriate. A single list was generated for each
comorbidity measure and duplicate entries deleted. A
final logic check was performed by a single clinician.
Co-morbidity characteristics of a hip fracture cohort
The CPRD is an ongoing primary care database of med-
ical records provided by General Practitioners [15]. It is
owned by the Medicines and Healthcare products Regu-
latory Agency (MHRA) and collects data about more
than 11.3 million patients from 674 individual GP prac-
tices. Approximately 6.9% of UK residents are currently
represented by data in the CPRD and these are broadly
representative of the wider UK population. General
Practitioners in the UK maintain each patient’s entire
healthcare record and should receive correspondence
(including Emergency Department correspondence, out-
patient clinic letters, and hospital discharge summaries)
from secondary care providers. Important events (e.g.
hip fracture) and diagnoses (e.g. interstitial lung disease)
should therefore be coded into the GP record even if the
patient was treated in hospital.
A cohort of patients (cases) were identified from
CPRD GOLD practices based on a first ever record of
“hip fracture” occurring between 1st January 1999 and
9th October 2013. The diagnostic and procedural codes
used to define this hip fracture cohort are presented in
Additional file 4 In addition, the patients required at
Fig. 2 Flow diagram showing the exclusion of Elixhauser co-morbidity Read codes
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least 3 years up-to-standard (UTS) registration in CPRD
GOLD prior to their hip fracture [15]. Age- and sex-
matched controls were identified by the CPRD in a 2:1
ratio from patients registered with practices from 1st
January 1996 onwards and with at least three preceding
years UTS registration.
The specific variables extracted from the CPRD were
age, sex, date of hip fracture diagnosis, and individual
comorbidities. For the principal analysis, diagnostic
codes were extracted from each patient’s entire lifetime
primary care record. We also planned sensitivity analyses
that confined comorbidities to those recorded within 1-
and 5-years of the index hip fracture.
Validating the predictive properties of the Elixhauser
method
The EM was tested against the CCI, using both the 17-item
original version by Charlson et al [1] and the shorter 12-
item modification proposed by Quan et al [6]. We planned
to report 30- and 365-day mortality. Kaplan-Meier plots
were created for death within 365 days by categories of CCI
and EM. Logistic regression models were fitted with 30-
and 365-day mortality as the dependent variables. The cov-
ariables were age (as a continuous variable) and sex, which
is consistent with the approach taken by other studies de-
signed to evaluate comorbidity summary measures. The
subsequent analyses fitted multivariable logistic regression
models with age and sex as well as either CCI or Elixhauser
comorbidities as covariables. Stepwise variable selection
techniques were not used. The comorbidity summary mea-
sures were then layered on top of this base model. Tests of
equality for Receiver Operating Characteristic (ROC) areas
were undertaken using the roccomp [31] module in Stata
v.15.0 (College Station, TX, USA). Although summary ta-
bles were produced to show the number of EM comorbidi-
ties in each group, these were included as separate
independent variables within regression models in the man-
ner proposed by Elixhauser et al. [2]. The principal analysis
used CCI calculated using the weights originally proposed
by Charlson et al. [1]. We reported the predictive properties
of the EM and CCI in both diseased (i.e. hip fracture) and
non-diseased (age- and sex-matched control) populations.
Importantly, we undertook analyses of cases and controls
separately and did not plan to utilize a case-control design.
In addition, we undertook sensitivity analyses limited to co-
morbidities documented 1- and 5-years before the index
hip fracture as some researchers may find themselves work-
ing with cuts of data that are limited in time. The principal
analysis used all comorbidies documented at any time in
each patient’s complete medical record.
Information governance
Ethical approval was not sought in line with the latest
Governance Arrangements for Research Ethics
Committees (GafREC) guidance [32]. Approval to use
the data was provided by the Independent Scientific Ad-
visory Committee (ISAC) at the MHRA (ISAC Protocol
No. 13_069RA). Personal data was processed under Arti-
cles 6 (1)(f ) and 9 (1)(f ) of the General Data Protection
Regulation (EU 2016/6709).
Results
Defining an Elixhauser coding algorithm
Figures 1 and 2 show the number of diagnoses identified
and eliminated for CCI and EM respectively. The final
lists included 5832 individual codes representing CCI
comorbidities (Additional file 1) and 7156 EM comor-
bidities (Additional file 2).
Comorbidity characteristics of a patient cohort
The linked dataset included 13,974 patients with hip
fractures and 26,860 age- and sex-matched controls. The
median age across the cohort was 82 years (interquartile
range [IQR]: 75–87 years and 75.1% were female. The
distribution of comorbidities within the cohort accord-
ing to Charlson and Elixhauser are shown in Figs. 3 and
4. Table 1 shows that 27.6% of hip fracture patients did
not have any CCI co-morbidities recorded; only 9.2% did
not have EM conditions recorded. The median CCI was
1 (interquartile range [IQR] 0–3) and EM 2 (IQR 1–4).
30-day mortality The EM improved the ability of a lo-
gistic regression model (using age and sex as covariables)
to predict 30-day mortality (AUROC 0.744 [95% CI
0.727 to 0.760] versus 0.686 [0.668 to 0.705]) among
cases. The EM alone performed better than CCI in pre-
dicting 30-day mortality (AUROC 0.696 [95% CI 0.677
to 0.714] versus 0.601 [0.582 to 0.619]). Similar findings
were observed within the control population: EM + base
model AUROC 0.771 (95% CI 0.743 to 0.800) versus EM
alone 0.709 (0.678 to 0.740) and EM 0.726 (0.692 to
0.760) versus CCI 0.649 (0.614 to 0.683).
365-day mortality Fig. 5 shows that the EM modestly
improved the ability of the base regression model to pre-
dict 365-day mortality (AUROC 0.726 [95% CI 0.716 to
0.735] versus 0.676 [0.665 to 0.687]) amongst cases. Fig. 6
shows that the CCI only performed marginally better
than the base model: AUROC 0.676 [95% CI 0.665 to
0.687]. The EM alone performed better than the CCI
(0.672 [95% CI 0.661 to 0.683]) versus 0.611 [95% CI
0.600 to 0.622]). Similar findings were observed within
the control population: EM + base model AUROC 0.750
(95% CI 0.740 to 0.759) versus EM alone 0.700 (0.690 to
0.710) and EM 0.696 (0.685 to 0.707) versus CCI 0.635
(0.622 to 0.645).
Use of diagnoses recorded over different durations
The proportion of patients with a CCI of zero decreased,
consistent with expectations, as the length of time over
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which diagnostic codes were assessed increased, e.g.
64.1% cases had CCI = 0 at 1-year versus 42.9% at 5-year
and 27.6% using the complete record. A similar trend
was observed for the number of EM co-morbidities, al-
though the difference between 1 and 5 years was less
marked (cases 1-year 48.4% versus 5-year 48.3% and
complete record 9.2%). The increased capture of diag-
nostic codes by using the complete primary care record
only modestly improved the predictive value of either
the CCI (1-year AUROC 0.574 [95% CI 0.555 to 0.572]
versus 5-year 0.591 [0.572 to 0.610] versus complete rec-
ord 0.605 [0.586 to 0.623]) or the EM (1-year 0.645
[0.625 to 0.664] versus 5-year 0.676 [0.657 to 0.696] ver-
sus complete record 0.695 [0.677 to 0.714) for 30-day
mortality amongst cases. Similar results were observed
amongst controls (Additional file 5).
Use of updated Charlson comorbidity index
The updated CCI described by Quan et al [6] performed
similarly in this population to the original index, both
for 30- (AUROC 0.716 [95% CI 0.699 to 0.733] versus
0.704 [0.686 to 0.721]), and 365-day mortality (AUROC
0.713 [95% CI 0.703 to 7.23] versus 0.700 [0.690 to
0.710]). The modified weights proposed by Quan et al
[6] have been included as an additional column in Add-
itional file 1.
Use of Charlson co-morbidities as individual co-variables
The Charlson co-morbidities performed marginally bet-
ter for predicting 30-day mortality when included as in-
dependent co-variables than when used as a single
index, both amongst cases (individual co-variables 0.632
[0.612–0.652] versus CCI 0.612 [0.594–0.631]) and con-
trols (0.679 [0.642–0.715] versus 0.660 [0.625–0.693]).
This also held for predicting 365-day mortality amongst
cases (CM 0.638 [0.627–0.649] versus CCI 0.616 [0.605–
0.628]) and controls (individual co-variables 0.662
[0.650–0.674] versus 0.640 [0.628–0.651]).
However, the EM continued to outperform the Charl-
son co-morbidities in predicting 30-day mortality, even
when diagnostic categories were used as individual co-
variables (cases: EM 0.695 [0.677–0.714] versus Charlson
co-morbidities 0.632 [0.613–0.652] and controls: 0.695
[0.677–0.714) versus 0.632 [0.613–0.652)). The EM also
outperformed individual Charlson co-morbidities in
predicting 365-day mortality (cases: EM 0.672 [0.661–
0.683] versus CM 0.638 [0.627–0.649] and controls:
0.696 [0.685–0.707] versus 0.662 [0.650–0.674]).
Fig. 3 Proportion of cases and controls with each Charlson co-morbidity
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Discussion
The principal aim of this study was to transparently and
reproducibly create comorbidity lists for future re-
searchers working with Read-coded databases. The final
lists are available as Additional files 1 and 2 that can be
readily imported into commonly used statistical software
packages (Additional file 1 and Additional file 2). These
lists are particularly important for researchers analyzing
UK primary care datasets such as Clinical Practice
Research Datalink (CPRD) GOLD [15] and The Health
Improvement Network (THIN) [16]. Although such re-
searchers may need to include a composite comorbidity
Fig. 4 Proportion of cases and controls with each Elixhauser co-morbidity
Table 1 Diagnosis count using Charlson and Elixhauser co-
morbidity lists
Count Charlson (%) Elixhauser (%)
Cases Controls Cases Controls
0 27.6 36.6 9.2 15.3
1 23.8 23.8 16.9 21.2
2 18.3 16.9 19.1 20.8
3 12.4 10.7 18.4 16.5
4 8.0 5.9 14.1 11.5
5 4.3 3.1 9.7 7.2
> 6 5.6 3.0 12.5 7.5
Fig. 5 Receiver-Operating Characteristic (ROC) curves for a regression
model (co-variables: age and sex) predicting 365-day mortality amongst
cases with and without the EM
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score for the purposes of risk adjusting outcomes, it is
onerous and time-consuming to create comprehensive
code lists for indices such as the EM, which encompasses
31 individual disease categories. This is particularly diffi-
cult for Read-coded databases as the Read syntax includes
codes along multiple axes, e.g. diseases, procedures, exam-
ination findings, and administrative events such as clinic
referrals. Read terms also include spelling errors (e.g.
“[V]Folow-up exam aft other treatment for malignant neo-
plasm”, inconsistent abbreviations (“[X]Vit B12/folic/oth
ant-megalobl-anaem caus adv ef ther use”, obscure dis-
eases (e.g. “Sequoiosis (red-cedar asthma)”), and synonyms
(“Plummer - Vinson syndrome” versus “Plummer-Vinson
syndrome”) that can lead to codes being missed. Publicly-
accessible lists of diagnostic codes for both the CCI and
EM will save analyst time and improve the reproducibility
of primary care research.
We have been unable to identify any previous attempts
to translate the EM (initially published using ICD-9-CM
codes) for use in Read-coded databases. Although the
CCI is the most commonly used comorbidity index in
studies with administrative data [4], it has less predictive
value than the EM in many populations. An earlier study
[13] reported such a list for CCI but identified 3156
codes, which is only 54% of those identified by our
study. Our study should not be interpreted as criticism
of these authors but as an extension of their work as we
used their findings – together with those published by
other single disease studies – to help create our own
CCI list. However, the differences between the two stud-
ies highlights the difficulties that research groups face
when trying to create comprehensive lists of Read codes
and employ them in adequately risk-adjusted research.
This study also showed that the EM performed better
than the CCI at predicting hip fracture mortality. How-
ever, even the EM only added a modest degree of add-
itional predictive value over and above a simple
regression model with age and sex covariables. Although
diagnostic codes from the entire lifetime record of pa-
tients added predictive value beyond those recorded
within the preceding 1- and 5-years, this increase was
modest. It is likely that comorbidities recorded within
the previous 12-months will be sufficient for risk adjust-
ment in most studies. These findings should reassure
researchers that are necessarily working with limited ex-
tracts of primary care data.
Limitations
The main limitation of our study is that it is difficult to be
certain that all diagnoses were included within each cat-
egory. However, we did use a number of strategies to
maximize our capture of relevant codes, including screen-
ing by independent clinicians and checks using lists cre-
ated by other researchers for specific disease populations.
It is also possible that discrepancies could arise in terms of
disease classification. For example, lymphoepithelial
carcinoma was categorized as “solid tumour” for the pur-
poses of the EM rather than “lymphoma”. These decisions
were aided by recourse to the ICD-9-CM codes used in
previous publications as well as textbooks and subject ex-
perts. It is, however, possible that some classifications will
be contentious or change over time. Although this
resource is likely to be sufficient for the purposes of co-
morbidity risk adjustment, researchers working on specific
disease processes should satisfy themselves that these lists
are sufficient for their purposes.
Conclusion
We have adopted a robust and transparent approach to
identifying Read codes that can be used by future re-
searchers to calculate CCI and EM. This study also
showed that, although the EM outperforms the CCI and
models are improved by using comorbidity codes cap-
tured over a long period of time, the differences are
modest. Researchers with access to limited datasets con-
cerning comorbidities may create logistic regression
models with similar discrimination to those with access
to complete healthcare records.
Additional files
Additional file 1: Read codes for Charlson co-morbidities. (CSV 417 kb)
Additional file 2: Read codes for Elixhauser co-morbidities. (CSV 513 kb)
Additional file 3: Screening Principles. (DOCX 120 kb)
Fig. 6 Receiver-Operating Characteristic (ROC) curves for a
regression model (co-variables: age and sex) predicting 365-day
mortality amongst cases with and without the CCI
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Additional file 4: Read codes used to identify the hip fracture cohort.
(DOCX 126 kb)
Additional file 5: Effect of using diagnostic records over different
durations. (DOCX 20 kb)
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